- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PPHM Market Currents
more »
-
Monday 8:32 AM Peregrine Pharmaceuticals (PPHM) +22.7% premarket after announcing positive top-line results from a Phase IIb trial of its bavituximab lung cancer treatment. Data showed a doubling of overall response rates and an improvement in progression-free survival in patients receiving the treatment.
Comment![Healthcare, On the Move]
PPHM in Focus
more »
PPHM Related Articles
more »
PPHM News
more »
-
at MarketWatch.com (Mon, 4:22PM)
-
at MarketWatch.com (Dec 29, 2011)
-
at MarketWatch.com (Dec 6, 2011)
-
at MarketWatch.com (Dec 30, 2010)
-
at MarketWatch.com (Dec 20, 2010)
PPHM Press Releases and Filings
more »
-
Marketwire (Mon, 7:30AM)
-
Marketwire (May 10, 2012)
-
Marketwire (Apr 26, 2012)
-
Marketwire (Apr 4, 2012)
-
Marketwire (Apr 3, 2012)
PPHM Latest Transcript
more »
PPHM Cramer
more »
Currently, there are no Cramer articles on PPHM.
PPHM Instablog posts
more »
PPHM vs. ETF Alternatives
Company Description
We are a clinical stage biopharmaceutical company that manufactures and develops monoclonal antibodies for the treatment of cancer and serious viral infections. We are advancing three separate clinical programs with our novel compounds bavituximab and Cotara® that are the first clinical... More
